Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03245632|
Recruitment Status : Not yet recruiting
First Posted : August 10, 2017
Last Update Posted : August 10, 2017
|Condition or disease||Intervention/treatment|
|Klebsiella Pneumoniae Infection||Other: Carbapenem-Resistant Klebsiella pneumoniae|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||800 participants|
|Target Follow-Up Duration:||2 Months|
|Official Title:||Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China|
|Estimated Study Start Date :||August 2017|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||December 2019|
Carbapenem-Resistant K. pneumoniae
Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
Other: Carbapenem-Resistant Klebsiella pneumoniae
no intervention, this is an obervational study.
Carbapenem-Sensitive K. pneumoniae
Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
- CRKP infection [ Time Frame: 7 days ]Culture postitive results confirmed the infection of CRKP
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03245632
|Contact: Ying-zhi FANG, Master||+86 email@example.com|
|Sir Run Run Shaw Hospital|
|Hangzhou, Zhejiang, China, 310016|
|Principal Investigator:||Yun-song YU, Doctor||Sir Run Run Shaw Hospital|